Treatment of Fatty Liver with Fibrosis

Risk Stratification and Treatment Intensity

The American Association for the Study of Liver Diseases recommends that patients with stage F2 or greater fibrosis should be considered for pharmacologic therapy in addition to lifestyle changes, as this stage is an independent predictor of liver-related complications and mortality 1, 2
Patients with F0-F1 fibrosis should focus exclusively on lifestyle modifications and metabolic comorbidity management, while those with F2-F3 fibrosis require lifestyle modifications plus consideration of pharmacologic therapy and hepatology referral 1, 2, 3
Patients with F4 fibrosis require all of the above plus hepatocellular carcinoma surveillance every 6 months 2, 3

The American College of Gastroenterology recommends a weight loss target of 7-10% to improve steatohepatitis and may improve fibrosis 1, 5, 3
A weight loss of 5-7% reduces hepatic fat content and inflammation, while a weight loss of ≥10% achieves fibrosis improvement in 45% of patients 1, 2, 3
The American Heart Association recommends a Mediterranean diet pattern with specific caloric restriction, including a caloric deficit of 500-1000 kcal/day reduction 1, 5
Aerobic exercise, such as 150-300 minutes/week of moderate-intensity or 75-150 minutes/week of vigorous-intensity exercise, reduces hepatic fat independent of weight loss 9, 8, 4

The American Association for the Study of Liver Diseases recommends pharmacologic treatment for patients with NASH or ≥F2 fibrosis to improve long-term prognosis and prevent progression to cirrhosis 1, 2, 6
GLP-1 receptor agonists, such as liraglutide, are preferred for patients with type 2 diabetes and fibrosis, as they have demonstrated NASH resolution in 39% vs 9% placebo after 48 weeks in biopsy-proven NASH 5, 8
Statins are safe and strongly recommended for patients with fatty liver and fibrosis, as they reduce hepatocellular carcinoma risk by 37% and hepatic decompensation by 46% 7, 8, 3

The American College of Gastroenterology recommends hepatocellular carcinoma surveillance every 6 months for patients with advanced fibrosis (F3) or cirrhosis (F4) 2, 3
Variceal screening is required for patients with liver stiffness ≥20 kPa or thrombocytopenia, and monitoring of liver function tests and non-invasive fibrosis markers should be done every 6-12 months depending on fibrosis stage 4